ULTIMOVACS
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs that require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe and the USA. The company and its proprietary technology are based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is a limited public liability company listed on the Oslo Stock Exchange in Norway.
ULTIMOVACS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2011-01-01
Address:
Oslo, Oslo, Norway
Country:
Norway
Website Url:
http://www.ultimovacs.com
Total Employee:
11+
Status:
Active
Total Funding:
270 M NOK
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress LetsEncrypt SSL By Default IPv6
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Fagron SA
Fagron is a pharmaceutical company specializing in chemicals, equipment, and supplies solutions.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
IVERIC bio
IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Stroma Biosciences
Stroma Biosciences is a biopharma company that develops stroma therapies to tackle cancer.
Vaxxit
Vaxxit is a biopharmaceutical company developing vaccines against HIV.
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.ultimovacs.com Semrush global rank: 7.86 M Semrush visits lastest month: 684
- Host name: 67.207.77.236
- IP address: 67.207.77.236
- Location: Frankfurt am Main Germany
- Latitude: 50.1188
- Longitude: 8.6843
- Timezone: Europe/Berlin
- Postal: 60313
More informations about "Ultimovacs"
About Ultimovacs
Ultimovacs is a clinical-stage biotechnology company developing novel immunotherapies against cancer. The product candidate UV1 is an off-the-shelf therapeutic cancer vaccine designed to …See details»
Ultimovacs - Crunchbase Company Profile & Funding
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.See details»
Investors - Ultimovacs
List of events where the Ultimovacs team will attend or present. Read more; E-mail: [email protected] [email protected] [email protected]. Phone number: +47 413 …See details»
Ultimovacs ASA - LinkedIn
Ultimovacs is a biotech company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against …See details»
Ultimovacs Company Profile: Overview and Full News Analysis
Ultimovacs is a biotech company based in Oslo that is focused on developing innovative immunotherapies to combat cancer. Their mission is to enhance and prolong the lives of …See details»
Ultimovacs - Funding, Financials, Valuation & Investors - Crunchbase
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.See details»
Ultimovacs Company Profile - Craft
Jan 28, 2021 Ultimovacs is a pharmaceutical company developing immunotherapies against cancer. Its lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell …See details»
Ultimovacs - Products, Competitors, Financials, Employees, …
Ultimovacs will provide an update on this technology platform to the market before the end of 2024. DOVACC (ovarian cancer): Evaluating olaparib and durvalumab +/- UV1 vs. olaparib …See details»
Annual Report 2020 - Ultimovacs
6 ULTIMOVACS 2020 DIRECTORS’ REPORT Overview of 2020 The Ultimovacs team can look back on 2020 as an eventful and successful year. As we outlined in last year’s annual report, …See details»
Ultimovacs Company Profile 2024: Stock Performance & Earnings
Ultimovacs General Information Description. Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a …See details»
Ultimovacs ASA Reports Third Quarter 2023 Financial Results and ...
Oslo, November 8, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its third quarter …See details»
Ultimovacs - Oslo Cancer Cluster - Innovation Park
Ultimovacs is a small pharmaceutical company developing novel immunotherapy against cancer. Our leading product is UV1, a therapeutic cancer vaccine (TCV) directed against human …See details»
Ultimovacs ASA announces revised terms of the employee share …
Jun 24, 2024 Ultimovacs has during the second quarter of this year implemented a cash preservation program that includes downsizing of the organization. As a measure to stimulate …See details»
Ultimovacs provides update from Phase I study in malignant …
Ultimovacs ASA. All patients in the trial who were alive at 3 years remain alive at 4 years (69.5%) with a minimum follow-up period of 4 years (median 53.0 months)See details»
Ultimovacs ASA: Annual Report 2021
Oslo, 25 March 2021: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces that the Board of Directors of Ultimovacs …See details»
Contact us - Ultimovacs
Ultimovacs ASA E-mail: [email protected] [email protected] [email protected]. Phone number: +47 413 80 080 Ullernchausséen 64 0379 Oslo Norway View in Google Maps. …See details»
Ultimovacs ASA Reports Third Quarter 2024 Financial Results and ...
Oslo, November 6, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its …See details»
Ultimovacs provides update from Phase I study in malignant
Jun 11, 2024 Ultimovacs is a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines. The lead cancer vaccine candidate UV1 is an off-the-shelf vaccine directed …See details»
Financial reports - Ultimovacs
Ultimovacs – Investors – Financial reports. Financial reports. 2024. Q3 2024 report and presentation; Q2 2024 report and presentation; Q1 2024 report and presentation; 2023. …See details»